South Asia achieves record immunization coverage; India, Nepal lead progress: WHO-UNICEF
WHO
) and
UNICEF
for 2024.
India reduced its number of
zero-dose children
- those who have not received a single
vaccine
- by 43 per cent, from 1.6 million in 2023 to 0.9 million in 2024. Nepal achieved a 52 per cent reduction, from 23,000 to 11,000, a WHO statement said.
Pakistan also recorded its highest-ever DTP3 (Diphtheria, Tetanus, Pertussis) coverage at 87 per cent. However, Afghanistan continued to struggle, with the lowest coverage in the region and a one percentage point decline since last year, it added.
The progress marks a milestone in the region's efforts to protect every child from vaccine-preventable diseases.
"This is a proud moment for South Asia. More children are protected today than ever before, thanks to tireless frontline health workers, strong government leadership, donors' and partners' support and the unwavering trust of families," said Sanjay Wijesekera, UNICEF Regional Director for South Asia.
"But we cannot forget the millions of children who are under-vaccinated or unvaccinated. Now is the time to push further, especially into the most rural areas, to give every child his or her right to healthcare in the earliest years of life," he said.
In 2024, 92 per cent of infants in South Asia received the third dose of the
DTP vaccine
- a crucial global indicator - up two percentage points from 2023. The first-dose DTP coverage rose from 93 to 95 per cent, showing a strong recovery beyond pre-COVID levels, the statement said.
There was also a 27 per cent drop in zero-dose children across the region, from 2.5 million in 2023 to 1.8 million in 2024.
The region also made significant strides in measles control. In 2024, 93 per cent of infants received the first dose and 88 per cent the second dose of the
measles vaccine
, up from 90 per cent and 87 per cent respectively. Measles cases fell 39 per cent -- from over 90,000 in 2023 to about 55,000 this year. However, coverage still remains below the 95 per cent threshold needed to prevent outbreaks, the statement said.
"It is heartening to see WHO South-East Asia Region reach the highest ever immunization rates, surpassing the pre-pandemic up-trend. We must build on this momentum and step up efforts to reach every child with these lifesaving vaccines. Together we can, and we must," said Dr Thaksaphon Thamarangsi, Director Programme Management, WHO South-East Asia Region.
HPV vaccination
coverage for adolescent girls rose from 2 per cent in 2023 to 9 per cent in 2024. Bangladesh made significant progress, vaccinating over 7.1 million girls since launching its programme in 2023. Bhutan, Maldives, and Sri Lanka also increased their HPV coverage by 3 percentage points (91 per cent to 94 per cent), 15 points (60 per cent to 75 per cent), and 17 points (31 per cent to 48 per cent) respectively.
Nepal launched its national HPV vaccination campaign in February 2025 and has vaccinated over 1.4 million girls. India and Pakistan are expected to roll out their HPV vaccination programmes later this year, the statement said.
Behind these gains are sustained government efforts, investments, policies, and the dedication of frontline and community health workers-many of them women-alongside donor and partner support. Use of digital tools, improved data systems, and targeted outreach campaigns have also played a key role, it said.
While significant progress was made, over 2.9 million children in the region remain un- or under-vaccinated and therefore unprotected, the statement said.
With this in mind, UNICEF and WHO urged governments in South Asia to sustain political commitment, increase domestic financing for immunization, expand HPV vaccine coverage, and intensify efforts to reach zero-dose and under-vaccinated children. They also called for greater investment in frontline health workers and reinforcement of surveillance systems for vaccine-preventable diseases.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
35 minutes ago
- Mint
The world is winning the war on cancer
IN 1971 RICHARD NIXON, then America's president, announced a 'war on cancer". Just two years earlier the Apollo programme had combined big science and big government to put astronauts on the Moon, so hopes were high. Some optimistic doctors talked of a cure for cancer within a few years. They were wrong. Today every adult has had cancer, knows someone who has, or both. Half of men and a third of women in rich countries can expect to suffer from it at some point in their lives. In America, where it is the second-most-common cause of death, just behind heart disease, it kills around 600,000 people a year. Worldwide, it is responsible for about one in six of all deaths. If your criterion for success was a cure within a decade—or even two or three or four—then you might conclude that the war on cancer has been lost. In fact, things are better than many realise. The progress is plain from the data and there is every reason to think it will continue. Cancer is related to age. If you strip out longer lifespans, it becomes clear that in the rich world the early 1990s were an inflection point. Since then, the age-adjusted death rate has been falling, slowly but steadily, year after year. In America the rate is now about a third lower than in the 1990s. The trend is similar in other developed countries. What some scientists hoped would be a blitzkrieg has turned out to be a steady but successful war of attrition. Some victories have been spectacular. Childhood leukaemia used to be virtually a death sentence; now it has a five-year survival rate above 90%. Yet because cancer is not one illness, but a whole category, much of the progress has come not from big breakthroughs, but thousands of smaller advances in screening, surgery and drugs. Future gains will come from three main sources. Some will come by applying lessons from the rich world all across the globe. The overlooked success story in the fight against cancer has been prevention—perhaps because cancers that never happen are less visible than those that are cured. For example, smoking rates have plummeted in rich countries. That has probably prevented more than 3m cancer deaths since 1975 in America alone. Because smoking still causes one in five cancer deaths around the world, anti-tobacco drives in poor and middle-income countries, where smoking remains common, stand to do an enormous amount of good. Another source of progress will be cheaper medicines and extra wealth to pay for them. Cervical cancer is one of the most common cancers in women. Almost all cases are the delayed side-effect of infection with the human papillomavirus (HPV), a bug. In 2008 Britain began offering a newly developed HPV vaccine to teenage girls. A decade and a half later, rates of cervical cancer among women in their 20s are down by 90%, and British health officials talk of virtually eradicating cervical cancer by 2040. The original HPV vaccine was relatively expensive. But a cheaper version developed in India now underpins a mass-vaccination campaign in that country, too. And the last source of progress will be the clinical application of fresh science. This comes in two steps: identifying who is most at risk of developing a cancer, and then finding ways to stop the disease in its tracks. As we report this week, both hold promise. Scientists already know of genetic variants that predispose their carriers to certain kinds of cancer, such as a faulty BRCA-1 gene that raises the risk of breast or prostate cancer. However, less than half of all cancer patients have a known risk factor. Similarly, only some pre-cancerous cells turn malignant. For example, bowel cancers tend to emerge from polyps, but only 5-10% of polyps become cancerous. The aim is to untangle this confusion in order to identify patients very early, when treatment is most effective. That work draws on huge biobanks of tissue samples and on the ability to watch genes switch on and off in living cells—impossible even a decade ago. Armed with new biomarkers in blood or breath and a deeper understanding of how combinations of genes and environmental exposure predispose people to develop cancers, physicians can target those who would benefit from treatment. That is important to prevent people undergoing needless surgery, chemo- and radiation therapy, at vast expense and with severe side-effects. Having worked out whom to treat, doctors can make use of an expanding arsenal of therapies. Some cheap drugs seem to act as cancer prophylactics. Aspirin, a painkiller, seems to cut the risk of bowel cancer in half when given to those with Lynch syndrome, a genetic disorder that predisposes sufferers to some types of cancer. Metformin, a cheap diabetes drug, cuts the risk of recurrence in women who have been treated for a particular type of breast cancer. GLP-1 receptor agonists such as Ozempic show promise, too. Alongside the mainstays of surgery, chemotherapy and radiotherapy a new technique is emerging that harnesses the power of the immune system. The idea is to boost the body's own ability to attack cancerous cells. Some vaccines—perhaps genetically tailored to individual patients—can target a cancer that is already established. Others, acting more like broad vaccines used against diseases such as the flu, could target pre-cancerous cells. Vaccines of this sort for breast and colon cancer are in clinical trials. Bucking onco Good news often goes unreported, especially if it happens gradually. That is the story of the war on cancer. Not everything is perfect: treatments are costly, drug firms worry about being sued for side-effects when treating people for diseases they do not yet have, and the Trump administration is planning steep cuts to the National Cancer Institute—setting back the science and putting off a generation of researchers. But costs will fall, treatments will find their way to market and work goes on in Europe and China, which this year overtook America as the main source of cancer research. That is why the age-adjusted death rate will continue falling, year after year.
India.com
4 hours ago
- India.com
A New HIV Shield: One Shot Every Six Months – Could This Be The Turning Point The World's Been Waiting For?
New Delhi: A new drug that could change the way the world prevents HIV has just received the green signal from the World Health Organization (WHO). Its name is Lenacapavir. And what makes it different? You only need it twice a year. The announcement came from Kigali, Rwanda, where global health experts gathered for the 13th International AIDS Society Conference on July 14. WHO shared new global guidelines to strengthen HIV prevention, and with it, officially recommended Lenacapavir as a key tool – especially for those who face high risk every day. They include sex workers, healthcare workers and people in close contact with HIV-positive individuals. This long-acting drug is not entirely new. The United States approved it earlier. Back in 2022, it was already being used to treat HIV-affected patients. Now, WHO's decision brings it into focus as a prevention method, specifically for pre-exposure prophylaxis (PrEP). WHO Director-General Dr. Tedros Adhanom Ghebreyesus said, 'We still do not have a vaccine for HIV. But this drug, taken only twice a year, is the best new option we have got.' Globally, the HIV burden remains heavy. In 2024 alone, 1.3 million people were infected. Lenacapavir is being hailed as a potential game-changer for global HIV prevention, particularly among communities like sex workers, transgender individuals, people in correctional facilities, men who have sex with men and those who inject drugs, all of whom have been disproportionately affected. Funding for HIV prevention is drying up in many regions. That is why this drug, which works longer and requires fewer doses, feels like a breakthrough. Lenacapavir is a product of U.S. biopharma giant Gilead Sciences. It belongs to a class of medicines called capsid inhibitors, which disrupt multiple steps in the HIV life cycle and help block the virus from replicating. What sets it apart is its long-acting nature. Just two injections a year are enough to offer sustained protection, a significant improvement over daily pills or monthly regimens that are harder to maintain. Compared to daily pills or monthly shots, Lenacapavir offers a simple solution – two injections a year. For those facing daily exposure to risk, this could be the protection they have been waiting for. The need for such interventions has never been more urgent. Over 1.3 million people contracted HIV in 2024 alone, according to WHO data. A large share of these infections occurred in low- and middle-income countries, where preventive care is either unavailable or underfunded. As funding for HIV prevention declines globally, a low-maintenance, highly effective drug like Lenacapavir could help reverse troubling trends. Public health experts say its biannual dosage makes adherence easier, especially for people with limited access to clinics or stigmatised by their communities. While the drug is yet to be rolled out widely, WHO has urged governments and NGOs to accelerate access through partnerships with local health systems. With global focus now shifting toward long-term, low-cost solutions, Lenacapavir offers a ray of hope in a decades-long battle against HIV.
Time of India
7 hours ago
- Time of India
Vidarbha becoming cancer capital, warns Datke
Nagpur: Raising alarm over the rising cancer cases in Vidarbha, BJP MLA Pravin Datke told the state assembly on Thursday that the region is fast becoming Maharashtra's "cancer capital" and called for immediate state-level intervention to improve awareness, and affordability, accessibility of cancer vaccines as well as diagnostic services. "Vidarbha is becoming the cancer capital. This isn't just a health crisis, it's a wake-up call," Datke said during a legislative discussion, urging the govt to subsidise cervical and breast cancer vaccines and promote early diagnosis through govt hospitals. Datke recalled the first community-driven initiative led by Nagpur-based corporator Rupa Rai under the CSR wing of Ankur Seeds and Birla Foundation. With support from Union minister Nitin Gadkari and CM Devendra Fadnavis, vaccines were made available to over 20,000 girls in Nagpur. "The vaccine initially cost a fortune, but thanks to Adar Poonawalla's contribution of 1.25 lakh doses to the state, it's now available at Rs945," he noted. The Nagpur Central MLA stressed that most citizens remain unaware or hesitant to take the vaccine due to myths and lack of outreach. "Cervical cancer is caused by a virus (HPV), and breast cancer is increasingly linked to genetics, hormonal treatment, and lifestyle changes. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Use an AI Writing Tool That Actually Understands Your Voice Grammarly Install Now We must launch an aggressive awareness campaign. Citizens should not fear cancer, they should fear ignorance," he said. Datke demanded that the state provide cervical and breast cancer vaccines under the MLA fund and recommended setting up a dedicated women's cancer hospital in Nagpur. He also asked the govt to make positron emission tomography (PET) scans — the essential first step in cancer detection — available free of cost at all govt hospitals. "The test alone costs Rs25,000, which makes early detection unaffordable for most," he added. He also appealed for municipal corporations and councils to reserve budgetary provisions specifically for cancer treatment, particularly for women. "Even though the govt has sanctioned Rs72 crore for a cancer hospital, only Rs15 crore was disbursed over the last three years," he said. Responding to the concerns, state health minister Prakash Abitkar acknowledged the urgency. "Awareness is critical. Many patients panic upon hearing the word 'cancer', when in reality, early detection improves outcomes significantly. We have already launched a strong campaign and are working on extending PET scan services under tertiary care," he assured. Abitkar also promised to discuss the proposal to allow vaccine procurement through MLA funds with deputy CM and finance minister Ajit Pawar. "We are committed to improving access and will pursue all necessary projects for Nagpur," he said.
